Chimeric Antibody c.8B6 to O-Acetyl-GD2 Mediates the Same Efficient Anti-Neuroblastoma Effects as Therapeutic ch14.18 Antibody to GD2 without Antibody Induced Allodynia-Reference-Cited by-同舟云学术

Chimeric Antibody c.8B6 to O-Acetyl-GD2 Mediates the Same Efficient Anti-Neuroblastoma Effects as Therapeutic ch14.18 Antibody to GD2 without Antibody Induced Allodynia

Published:2014-02-10 Issue:2 Volume:9 Page:e87210
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Terme Mickaël,Dorvillius Mylène,Cochonneau Denis,Chaumette Tanguy,Xiao Wenhua,Diccianni Mitchell B.,Barbet Jacques,Yu Alice L.,Paris François,Sorkin Linda S.,Birklé Stéphane

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference48 articles.

1. Neuroblastoma;JM Maris;Lancet,2007

2. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children’s oncology group study;KK Matthay;J Clin Oncol,2009

3. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma;AL Yu;N Engl J Med,2010

4. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells;E Barker;Cancer Res,1991

5. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma;NK Cheung;J Clin Oncol,1987

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy Options for Neuroblastoma: What is on the Horizon?;Current Molecular Biology Reports;2024-05-13

2. GD2-targeting therapy: a comparative analysis of approaches and promising directions;Frontiers in Immunology;2024-03-15

3. CD44v6, STn & O-GD2: promising tumor associated antigens paving the way for new targeted cancer therapies;Frontiers in Immunology;2023-10-03

4. Assessing Glycosphingolipid Profiles in Human Health and Disease Using Non-Imaging MALDI Mass Spectrometry;Applied Sciences;2023-09-01

5. Biology of GD2 ganglioside: implications for cancer immunotherapy;Frontiers in Pharmacology;2023-08-21